← Back to headlines
Bristol-Myers Squibb Raises 2026 Guidance, Milvexian AFib Readout Shifts
Bristol-Myers Squibb has increased its 2026 financial guidance, projecting 20-25% growth for Eliquis, while the readout for its milvexian AFib drug has been postponed to Q1 2027.
30 Jul, 19:25 — 30 Jul, 19:25
Sources
Showing 1 of 1 sources
